Obestatin is an endogenous peptide sharing a precursor with ghrelin. This study aims to investigate whether and how obestatin protects MES23.5 dopaminergic cells against 1-methyl-4-phenylpyridinium (MPP + )-induced neurotoxicity.
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-6 mol/L) for 20 min prior to incubation with 200 μmol/L MPP + for 12 or 24 h, or treated with obestatin alone (10 -13 to 10 -6 mol/L) for 0, 6, 12, and 24 h. The methyl thiazolyl tetrazolium (MTT) assay was used to measure cell viability. Flow cytometry was used to measure the caspase-3 activity and the mitochondrial transmembrane potential. Proliferating cell nuclear antigen (PCNA) protein levels were determined by Western blotting. Obestatin (10 -13 to 10 -7 mol/L) pretreatment blocked or even reversed the MPP + -induced reduction of viability in MES23.5 cells, but had no effect on MPP + -induced mitochondrial transmembrane potential collapse and caspase-3 activation. When applied alone, obestatin increased viability. Elevated PCNA levels occurred with 10 -7 , 10 -9 , 10 -11 and 10 -13 mol/L obestatin treatment for 12 h.
The results suggest that the protective effects of obestatin against MPP + in MES23.5 cells are due to its proliferation-promoting rather than anti-apoptotic effects.
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INTRODUCTION
Obestatin, a 23-amino-acid peptide hormone, was first discovered in 2005 [1] . It was originally extracted from rat stomach, and is present in the duodenum, gastric mucosa, colon, jejunum, spleen, pancreas, breast milk, mammary glands, plasma, saliva, and testis [2] . By binding to receptors
that have yet to be defined, obestatin has both central and peripheral actions, including regulation of energy homeostasis, hormone secretion, improving memory, regulating sleep, and inhibiting water drinking [3] [4] [5] [6] [7] [8] [9] [10] . To date, there are confl icting opinions on the relationship between obestatin and its possible receptors, G protein-coupled receptor-39 (GPR39) and glucagon-like peptide-1 receptor (GLP-1R) [1, 11, 12] . It has been reported that both GPR39 and GLP-1R might mediate the proliferative effects of obestatin through the phosphorylation of ERK1/2 [12, 13] .
Obestatin is derived from the post-translational cleavage of preproghrelin, the same peptide precursor as ghrelin. We previously reported that the neuroprotective effects of ghrelin are mediated by its anti-apoptotic action on dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-treated mice in vivo, and 1-methyl-4-phenylpyridinium (MPP + )-treated MES23.5 cells in vitro [14, 15] . In the present study, we tested whether obestatin had similar neuroprotective effects on MES23.5 dopaminergic cells, which express GPR39 (data not shown). The MES23.5 cell line is a neuroblastoma derived from somatic cell fusion [16, 17] , and expresses three characteristics of dopaminergic neurons, tyrosine hydroxylase positivity, expression of the omega-conotoxin 
MATERIALS AND METHODS

Materials
The primary antibody against proliferating cell nuclear heat-inactivated FBS [14, [18] [19] [20] [21] .
Methyl Thiazolyl Tetrazolium (MTT) Assay
To assess the neuroprotective effects of obestatin, To evaluate the proliferative properties of obestatin alone, 10 −6 to 10 −13 mol/L obestatin was applied to the cells and incubated for 24 h. All the subsequent procedures were as above.
Measurement of Mitochondrial Transmembrane
Potential (ΔΨm)
After pretreatment with different concentrations of obestatin emission by fl ow cytometry [14, 19, [22] [23] [24] .
Active Caspase-3 Assay
Caspase-3 activity was measured by fl ow cytometry using a PE-conjugated monoclonal active caspase-3 antibody apoptosis kit (BD Bioscience) [14, 19, 20] . After washing twice with cold phosphate-buffered saline, cells were resuspended in Citofix/Cytoperm™ (0.5 mL) at a density of 1×10 , or 10 -13 mol/L obestatin pretreatment (Fig. 2) . infl uenced by obestatin pretreatment (10 -7 , 10 -9 , 10 -11 , and 10 -13 mol/L) (Fig. 3) .
Obestatin Did Not
Obestatin Induced PCNA Up-regulation
The levels of PCNA, one of the markers of cell proliferation [25, 26] , were increased with 10 -9 mol/L obestatin treatment for 6 h, and peaked at 12 h. Other concentrations (10 -7 , 10 -11 , and 10 -13 mol/L) had the same effect. MPP + (200 μmol/L) down-regulated the PCNA protein level at 12 h, which was, however, restored and even reversed by obestatin pretreatment (10 -7 , 10 -9 , 10 -11 , and 10 -13 mol/L) for 20 min. These results indicated that obestatin at 10 -13 to 10 -7 mol/L has proliferative effects on MES23.5 cells (Fig. 4) . Since obestatin has the same peptide precursor as ghrelin, we first hypothesized that the protective effect of obestatin was anti-apoptotic, as we had shown for ghrelin [14, 15] . The neurotoxin that creates the classical cell Neurosci Bull February 1, 2014, 30(1): 118-124 122 model of Parkinson's disease [27, 28] , MPP + , is well-known to induce apoptosis by selectively damaging mitochondria [29] .
Mitochondrial dysfunctions play important roles in the pathogenic cascades of apoptosis, and are involved in the pathogenesis of Parkinson's disease [14, 30, 31] . However, we
showed that obestatin neither inhibited caspase-3 activation nor reversed the ΔΨm collapse induced by MPP + . This is in accord with studies showing that obestatin does not prevent the apoptosis induced by cytosine arabinoside in HL-1 cardiomyocytes [32] , and even aggravates apoptosis in pig ovarian cells [33] .
Moreover, we found positive results for PCNA expression, which was strongly suggestive of an effect of obestatin on proliferation in MES23.5 dopaminergic cells, in accord with other studies showing that obestatin stimulates proliferation in primary cultured human retinal epithelial cells [13] , human gastric cancer cells [34] , and pig ovarian granulosa cells [33] . Obestatin has been reported to induce the up-regulation of several proliferation markers, such as PCNA, cyclin B1, and mitogen-activated protein kinase [35] . The underlying mechanisms could be related to its binding with its receptor and the subsequent activation of PI3K, PKCε, and Src for ERK1/2 induction in vitro [12, 13, 34] . Activation of this signaling pathway might account for the proliferative effects on MES23.5 cells.
However, there is still controversy on the proliferative effect of obestatin. Some studies have revealed no effect of obestatin on cell viability in the mouse cardiomyocyte cell line HL-1 or 3T3-L1 preadipocytes [32, 36] . These results indicate that the proliferative effects of obestatin are tissue-specifi c.
In summary, we provide direct evidence that the protective effects of obestatin are due to its proliferative but not anti-apoptotic action in MES23.5 dopaminergic cells. For dopaminergic neurons in the central nervous system that cannot proliferate, obestatin might not act as a neuroprotective agent for Parkinson's disease. 
